Start free

Artiva Biotherapeutics, Inc. (ARTV) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 18, 2026.

Filings shown
58
Open-market buys
21
Open-market sells
26
Buys, 10b5-1 box not checked
21 of 21

Counts cover the 58 most recent Form 4 filings Tradune holds for ARTV (filed May 13 – Nov 18, 2026); the score below covers only the trailing 90 days (0 buys, 20 sells). SEC EDGAR Form 4 filings for ARTV last checked Nov 21, 2026, 09:00 UTC; the latest ARTV filing Tradune holds was filed Nov 18, 2026. This is not guaranteed to be the complete record — see ARTV's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 40 filings Tradune holds for ARTV filed Aug 31 – Nov 18, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

20 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
3 sales· 55,114 sh
checkbox disclosed
On filings with the box not checked
17 sales· 410,014 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Fred AslanChief Executive Officer 0 6 — 352,425 −$2,265,350
Subhashis BanerjeeChief Medical Officer 0 5 — 15,568 −$138,954
Christopher HoranChief Tech Operations Officer 0 4 — 51,675 −$310,288
Jennifer BushCOO, CLO, Compliance Officer 0 4 — 44,417 −$261,292
Gines Diego MirallesPresident & Head of R&D 0 1 — 1,043 −$4,080

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

0/ 100

Net insider sales
0 distinct buyers0 buy · 20 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at ARTV

Insiders reported 21 open-market purchases of ARTV between May 13, 2026 and Nov 18, 2026, across 2 distinct buyers. The most recent purchase was reported by Ra Capital Management, L.P. (Director, 10% owner) on Jul 31, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Gines Diego Miralles President & Head of R&D · filed Nov 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,043 $3.91 121,457 −0.9% Nov 17, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Christopher Horan Chief Tech Operations Officer · filed Nov 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 20,546 $3.91 281,775 −6.8% Nov 17, 2026
Jennifer Bush COO, CLO, Compliance Officer · filed Nov 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 19,217 $3.91 338,503 −5.4% Nov 17, 2026
Subhashis Banerjee Chief Medical Officer · filed Nov 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 4,037 $3.91 164,701 −2.4% Nov 17, 2026
Fred Aslan Chief Executive Officer · filed Nov 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 119,771 $3.91 1,337,657 −8.2% Nov 17, 2026
Christopher Horan Chief Tech Operations Officer · filed Nov 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 10,423 $4.18 302,321 −3.3% Nov 2, 2026
Jennifer Bush COO, CLO, Compliance Officer · filed Nov 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 8,439 $4.18 357,720 −2.3% Nov 2, 2026
Subhashis Banerjee Chief Medical Officer · filed Nov 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,110 $4.18 168,738 −0.7% Nov 2, 2026
Fred Aslan Chief Executive Officer · filed Nov 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 62,178 $4.18 1,457,428 −4.1% Nov 2, 2026
Fred Aslan Chief Executive Officer · filed Oct 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 23,463 $7.20 1,519,606 −1.5% Oct 6, 2026
Christopher Horan Chief Tech Operations Officer · filed Oct 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 10,340 $6.84 312,744 −3.2% Oct 5, 2026
Jennifer Bush COO, CLO, Compliance Officer · filed Oct 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 8,370 $6.84 366,159 −2.2% Oct 5, 2026
Subhashis Banerjee Chief Medical Officer · filed Oct 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,099 $6.84 169,848 −0.6% Oct 5, 2026
Fred Aslan Chief Executive Officer · filed Oct 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 61,696 $6.84 1,543,069 −3.8% Oct 5, 2026
Fred Aslan Chief Executive Officer · filed Sep 15, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 110,000 — 1,604,765 +7.4% Sep 15, 2026
Grant / award Employee Stock Option (Right to Buy) 315,000 — — — Sep 15, 2026
Ra Capital Management, L.P. Director, 10% owner · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Director Stock Option (Right to Buy) 16,250 — — — Sep 10, 2026
Fred Aslan Chief Executive Officer · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 45,000 — 1,494,765 +3.1% Sep 10, 2026
Grant / award Employee Stock Option (Right to Buy) 155,000 — — — Sep 10, 2026
Laura Stoppel Director · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Director Stock Option (Right to Buy) 16,250 — — — Sep 10, 2026
Elaine K. Sorg Director · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Director Stock Option (Right to Buy) 16,250 — — — Sep 10, 2026
Elizabeth L. Hougen Director · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Director Stock Option (Right to Buy) 16,250 — — — Sep 10, 2026
Brian Daniels Director · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Director Stock Option (Right to Buy) 16,250 — — — Sep 10, 2026
Daniel G. Baker Director · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Director Stock Option (Right to Buy) 16,250 — — — Sep 10, 2026
Alison Moore Director · filed Sep 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Director Stock Option (Right to Buy) 16,250 — — — Sep 10, 2026
Gines Diego Miralles President & Head of R&D · filed Sep 11, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 45,000 — 122,500 +58% Sep 9, 2026
Grant / award Employee Stock Option (Right to Buy) 135,000 — — — Sep 9, 2026
Christopher Horan Chief Tech Operations Officer · filed Sep 11, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award 40,000 — 323,084 +14% Sep 9, 2026
Grant / award Employee Stock Option (Right to Buy) 120,000 — — — Sep 9, 2026

Listing the 25 most recent of 58 Form 4 filings held for ARTV; the 33 older filings (filed May 13 – Sep 11, 2026) are counted above but not listed here — see ARTV's full Form 4 filing history on SEC EDGAR.

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to ARTV's (Nov 18, 2026).

Frequently asked about ARTV insider activity

How many insiders bought ARTV stock in these Form 4 filings?

2 distinct insiders at Artiva Biotherapeutics, Inc. reported 21 open-market purchases (Form 4 code P) of ARTV shares between May 13, 2026 and Nov 18, 2026, the most recent filed by Ra Capital Management, L.P. (Director, 10% owner) on Jul 31, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for ARTV?

The most recent Form 4 on this page was filed by Fred Aslan (Chief Executive Officer) on Nov 18, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market ARTV insider purchase shown?

The largest open-market purchase among the filings shown was 6,510,416 ARTV shares at $11.52 (about $74,999,992) by Ra Capital Management, L.P. (Director, 10% owner) on May 11, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent ARTV insider purchases have the Form 4 10b5-1 box checked?

No. All 21 ARTV open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Ra Capital Management, L.P. (Director, 10% owner) on Jul 31, 2026, 24,944 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for ARTV — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.